Trubion Pushing Forward Arthritis Trials, Working to Re-Ignite the Spark for Investors
Biotech, Arthritis, Trubion Luke Timmerman wrote: The stock chart for Trubion Pharmaceuticals tells an ugly tale this past year. The company had sunk to $4.48 as of yesterday’s close, after selling shares in an initial public offering at $13 in October 2006. Steven Harr, an influential biotech analyst at Morgan Stanley, summed it up in a report in March, saying Trubion “fits into the category of stock we have advised avoiding.” The stock is thinly traded (meaning any big buyers have to bid up
Mail this post 
Health is the Most Precious Asset to us! Just willing to share with you what I have learned from Nutriotional Immunology.
